Solas BioVentures recruits new partner Lana Caron to expand digital health and health tech practice

​

Lana Caron Will Build on the Firm’s Impressive History of Medtech and Biopharma Investments

 

Chattanooga, TN – September 14, 2023 — Solas BioVentures, a leading venture capital firm investing in early-stage biotech, medical device, and pharmaceutical companies, today announced the addition of senior healthcare technology executive and investor Lana Caron as General Partner.

 

Lana joins Solas to grow the firm’s digital health and health tech practice and build on Solas’s impressive track record, which includes early investments in well-known biopharma and medtech companies like Francis Medical, Vesalio, Arrivo BioPharma, and Tvardi Therapeutics. She will be based in Boston.

 

“Lana will be an exceptional addition to our investment team and resource for our portfolio company executives. Solas made a strategic decision to double-down on digital health and healthtech investing. We were lucky to find Lana Caron to help make that happen. The opportunity in Health Tech and Digital Health VC is massive and with Lana on board, we increase Solas’ capacity to pursue these opportunities and expand our investments into new categories,” said Dr. David Adair, Co-Founder and Managing Partner at Solas.

 

“I am ecstatic that Lana is a partner at Solas! Solas is known for its deep clinical and regulatory expertise, and entrenched relationships across biotech, pharma and medtech. We’re excited to bring a digital health and health tech veteran like Lana to help us capitalize on the ongoing convergence across medtech, biotech and pharma, and expand our digital portfolio,” said Michael Hoey, General Partner at Solas and Founder/CTO at Francis Medical. 

 

At Solas, Lana will lead the firm's due diligence efforts to fund breakthrough healthcare innovation made possible by AI and technology enabled medicine. Before joining Solas, Lana led digital health and health tech partnerships and investments at Philips Ventures, the venture capital arm of Philips. As an operator, Lana currently serves as Chief Business Development Officer at Vektor Medical, and previously served on leadership teams across a variety of health technology startups leading sales, marketing, and business development. Prior to getting the startup bug, Lana developed and executed inorganic strategies with deal values ranging from $15M to $200M at established technology companies as Director of Corporate Development at a $2B spin-off from Texas Instruments and Manager of Strategy & Business Development at a $1B division at Philips Healthcare. She began her career at Accenture in management consulting.

 

Lana is the latest addition to the Solas team of partners who leverage extensive operating, clinical and regulatory expertise to double down on early-stage opportunities in high-growth sectors.

 

About Solas BioVentures

Solas BioVentures invests exclusively in the life science industry, focusing on early-stage biotech, medtech and digital health companies. Our investment team combines decades of clinical, regulatory and operating experience across different verticals in healthcare. Founded in Chattanooga, TN, Solas is proud of its southern roots and founder-centric, patient-focused approach to foster breakthrough medicine and technology innovation. We put patients first. 

​

​